Back to News
May 18, 2026 4:00 PM

Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case

The U.S. Supreme Court declined to hear an appeal from Eli Lilly & Co. (NYSE:LLY), leaving in place a $194 million whistleblower judgment tied to allegations that the drugmaker underpaid Medicaid rebates by misreporting drug pricing data.

• Eli Lilly stock is trending lower. Why is LLY stock trading lower?

The Bloomberg report on Monday noted that the justices issued the decision without comment, rejecting Lilly's broader constitutional challenge to the federal False Claims Act.

The company argued the law improperly allows private individuals to sue on behalf of the government and receive a portion of any financial recovery.

According to Department of Justice data cited in the appeal, whistleblowers filed a record 979 False Claims Act lawsuits in fiscal 2024, while settlements and judgments topped $2.9 billion.